High‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma
Referencias
Additional references
Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. Journal of the American Medical Association (JAMA) 1969;208(9):1680‐5. [MEDLINE: 5818682]
Alexanian R, Dimopoulos M. The treatment of multiple myeloma. The New England Journal of Medicine 1994;330(7):484‐9. [MEDLINE: 8289856]
Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79(5):1130‐6. [MEDLINE: 1536941]
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine 1996;335(2):91‐7. [MEDLINE: 8649495]
Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Double Autologous Transplantation Improves Survival of Multiple Myeloma Patients: Final Analysis of a Prospective Randomized Study of the "Intergroupe Francophone du Myelome" (IFM 94). Blood. 2002; Vol. 100 (11) Suppl:5a‐6a (abstract 7).
Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93(1):55‐65. [MEDLINE: 9864146]
Bergsagel DE. Myeloma: Biology and Management. In: Malpas JS, Bergsagel DE, Kyle A, Anderson KC editor(s). Myeloma: Biology and Management. 2nd Edition. Oxford: Oxford University Press, 1998:269‐302. [ISBN: 0‐19‐262882‐8]
Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high‐dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplantation 1995;15(3):367‐71. [MEDLINE: 7599560]
Bladé J, Sureda A, Ribera JM, Diaz‐Mediavilla J, Garcia‐LaraÒa J, Palomera L, et al. High‐dose therapy intensification versus continued chemotherapy in responding multiple myeloma patients. Results of a prospective randomized trial from the Spanish Cooperative Group Pethema. The Hematology Journal. 2002; Vol. 3 Suppl 1:173‐4. [abstract: #0577]
Cavo M, Tosi P, Zamagni E, Cellini C, Ronconi S, De Vivo A, et al. The "Bologna 96" Clinical Trial of Single vs. Double Autotransplants for Previously Untreated Multiple Myeloma Patients. Blood 2002;100 (11) Suppl:179a (abstract 669). [abstract: #669]
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high‐dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95(12):4008‐10. [MEDLINE: 10845942]
Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. British Medical Journal 1994;309(6964):1286‐91. [MEDLINE: 7718048]
Djulbegovic B, Blumenreich M, Joseph G, et al. Melphalan‐prednisone v combined chemotherapy in multiple myeloma: A meta‐analysis. Blood. 1991; Vol. 78 Suppl:114a.
Dumontet C, Ketterer N, Espinouse D, Neidhardt EM, Moullet I, Thieblemont C, et al. Reduced progression‐free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplantation 1998;21(10):1037‐41. [MEDLINE: 9632278]
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842‐54. [MEDLINE: 1182674]
Durie BG. The epidemiology of multiple myeloma. Seminars in Hematology 2001;38 (2 Suppl 3):1‐5. [MEDLINE: 11309701]
Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High‐dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up‐front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92(9):3131‐6. [MEDLINE: 9787148]
Fermand JP, Marolleau JP, Alberti C, Divine M, Leblond V, Macro M, et al. In Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34 Enriched ABSC: Preliminary Results of a Two by Two Designed Randomized Trial in 230 Young Patients with Multiple Myeloma (MM). Blood 2001;98 (11 Suppl):815a (abstract 3387). [abstract: #3387]
Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2(8668):879‐82. [MEDLINE: 2571812]
Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology 1992;10(2):334‐42. [MEDLINE: 1531068]
Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, et al. Double‐intensive therapy in high‐risk multiple myeloma. Blood 1992;79(11):2827‐33. [MEDLINE: 1350228]
Jagannath S, Tricot G, Barlogie B. Autotransplants in multiple myeloma: pushing the envelope. Hematology/Oncology Clinics of North America 1997;11(2):363‐81. [MEDLINE: 9137975]
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2002;52(1):23‐47. [MEDLINE: 11814064]
Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42‐6. [MEDLINE: 11440947]
Kyle RA. Multiple myeloma: how did it begin?. Mayo Clinic Proceedings 1994;69(7):680‐3. [MEDLINE: 8015334]
Lévy V, Porcher R, Fermand JP, Katsahian S, Chevret S, Ravaud P. Evaluating high dose therapy in multiple myeloma: Use of quality‐adjusted survival analysis. Blood 2000;96 (11 Suppl):760a (abstract 3286). [abstract: #3286]
McElwain TJ, Powles RL. High‐dose intravenous melphalan for plasma‐cell leukaemia and myeloma. Lancet 1983;2(8354):822‐4. [MEDLINE: 6137651]
Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. Journal of the American Medical Association (JAMA) 2001;285(15):1987‐91. [MEDLINE: 11308435]
Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomedicine & Pharmacotherapy 2002;56(5):223‐34. [MEDLINE: 12199621; ISSN: 0753‐3322]
Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. Journal of Clinical Oncology 1998;16(12):3832‐42. [MEDLINE: 9850028]
Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose‐intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94(4):1248‐53. [MEDLINE: 10438712]
Palumbo A, Bringhen S, Rus C, Petrucci MT, Mandelli F, Musto P, et al. A Prospective Randomized Trial of Intermediate Dose Melphalan (100m/m²) vs Oral Melphalan/Prednisone: An Interim Analysis. Blood. 2001; Vol. 98 (11 Suppl):849a‐50a (abstract 3528). [abstract: #3528]
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. [MEDLINE: 9921604]
Rajkumar SV, Kyle RA, Gertz MA. Myeloma and the newly diagnosed patient: a focus on treatment and management. Seminars in Oncology 2002;29(6 Suppl 17):5‐10. [MEDLINE: 12520478]
Reece DE, Barnett MJ, Connors JM, Klingemann HG, O'Reilly SE, Shepherd JD, et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4‐hydroperoxycyclophosphamide. Bone Marrow Transplantation 1993;11(2):139‐46. [MEDLINE: 8435663]
Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31(1):150‐3. [MEDLINE: 11914311]
Schwartz J. Multinational trends in multiple myeloma. Annals of the New York Academy of Sciences 1990;609:215‐24. [MEDLINE: 2264645]
Segeren CM, Sonneveld P, Van Der Holt B, Vellenga E, Crookewit AJ, Verhoef GE, et al. Overall and event‐free survival are not improved by the use of myelo‐ablative therapy following intensified chemotherapy in previously untreated multiple myeloma patients: a prospective randomized phase III study. Blood 2003;101(6):2144‐51. [MEDLINE: 12456509]
Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93(1):51‐4. [MEDLINE: 9864145]
Verhagen AP, DeVet HCW, DeBie RA, Kessels AGH, Boers M, Bouter LM, et al. The Delphi List: A Criteria List for Quality Assessment of Randomized Clinical Trials for Conducting Systematic Reviews Developed by Delphi Consensus. Journal of Clinical Epidemiology 1998;51(12):1235‐41. [MEDLINE: 10086815]
Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High‐dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;84(3):950‐6. [MEDLINE: 7913845]
Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, et al. Autotransplants in multiple myeloma: what have we learned?. Blood 1996;88(3):838‐47. [MEDLINE: 8704239]
Weaver CH, Zhen B, Schwartzberg LS, Leff R, Magee M, Geier L, et al. Phase I‐II evaluation of rapid sequence tandem high‐dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplantation 1998;22(3):245‐51. [MEDLINE: 9720737]
Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973‐1995: a report card for the U.S.. Cancer 1998;82(6):1197‐207. [MEDLINE: 9506368]
